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Abstract 
Background: Breast cancer is the most common cancer and a major cause of death from cancer in women. 
Understanding the factors, which can predict directly and indirectly the final fate of patients, can be useful in 
clinical decision-making and treatment choices. 
Materials and Methods: In a retrospective descriptive-analytic study, 108 pathological samples of patients 
with primary breast cancer collected during 2011-2017 from the department of pathology in Imam Hossein 
Hospital (Tehran Iran). Classified regarding the association of stromal reactions in tumor tissue including 
necrosis rate, lymphocyte infiltrating rate, and tumor desmoplasia with different types of breast tumors 
including four groups of Basal like, HER2/neu, Luminal B, and Luminal A based on biological biomarkers. 
Results: Mean age of the patients was 50.84±13.25 years. No significant relationship was found between age 
and type of groups. Majority of patients (60%) were in the pathological grade 2. A significant relationship 
was observed between three groups of Luminal B, and Basal-like with Grade 2 (p<0.05). Most patients 
suffered from intermediate desmoplasia which was significant only between three groups of Luminal B, 
HER2/neu and Basal-like (p<0.05). In terms of tumor necrosis, the majority of patients in the HER2/neu and 
Basal-like groups indicated non-extensive necrosis, which was significant (p>0.05). In both groups of 
Luminal A and Luminal B, most patients had no necrosis while the relationship between necrosis and 
pathological type of tumor was significant only in the Luminal B group (p>0.05). No significant relationship 
was found between the number of lymphocytes and the type of tumor. 
Conclusion: This study indicated the relationship between pathological types of breast cancers based on 
biomarkers with pathological grade, necrosis ratio and tumor desmoplasia. Determination of the pathological 
type of tumor based on the status of biological markers (HER-2/neu PR, ER, Ki67) in patients with breast 
cancer is recommended for making decision about therapeutic plan.  
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Introduction 
Cancer as a major health problem of the century
1
 is 
the second cause of death after cardiovascular 
diseases
2
. Breast cancer is the most common invasive 
cancer among women that afflicting one in eight
3
 and 
the most significant cause of cancer deaths 
worldwide
4-6
. Despite the numerous advances in early 
diagnosis and treatment of this disease, breast cancer 
is still the main cause of death among women
7,8
. 
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Breast cancer has been the most common malignancy 
among Iranian women in recent years
9
. Age of breast 
cancer in Iranian population is ten years younger than 
other countries
10,11
. Approximately, 70% of Iranian 
women are at advanced stages of the disease, which 
cannot be treated by medical teams at this stage
12
. In 
addition, this disease clinically passes a long latent 
stage, which is about eight to ten years to transform a 
cancer cell into a palpable tumor. Thus, the patient 
can be saved from death by identifying and 
recognizing these tumors in the early stages
13
. As 
indicated, the invasive breast carcinomas, like other 
cancers, have genetic changes causing molecular and 
biological fragmentation characterized by microarray 
methods. Researchers hope to find such new 
divisions clarify the tumor biology, predict tumor 
status and better therapeutic strategies. Each of these 
molecular variations caused the 
immunohistochemical properties, which can be 
traced and categorized by conventional pathological 
techniques such as IHC, which are regarded as a 
guide to the prognosis of cancer and its invasive 
feature, metastasis rates, and measure the 
effectiveness of treatment and the appropriate 
therapeutic method to recognize the cancer 
recurrence. Different types of tumors 
Immunohistochemical markers for breast cancer in 
terms of application significance are as follows: 
Estrogen receptor (ER), Progesterone receptor (PR), 
Human Epidermal growth factor (HER2), Ki67. 
Based on the expression of the genetic profile, four 
subtypes were defined for breast cancer including 
luminal A, luminal B, HER2-overexpressing, and 
basal-like. 
Tumor markers for breast cancer include estrogen 
receptor (ER) and progesterone receptor (PR) in 
order of application significance which are used for 
investigating the necessity of hormone therapy. 
Human epidermal growth factor 2 (HER2) is a 170 
kDa glycogen protein, which is diagnosed by various 
methods such as IHC, FISH, Southern blot, and EIA, 
where the encoder is a tyrosine kinase receptor in the 
cell membrane. Based on these receptors, breast 
tumors are classified into luminal (ER +), HER2-
overexpressing (HER2) (ER-/HER2+) and triple 
negative (TN) (ER-, PR- and HER2-). The luminal 
tumors are classified into two groups of luminal A 
(HER2 and Ki67 less than 14%) and luminal B (HER2 
- / + and Ki67 more than 14%) according to HER2 and 
Ki67 in terms of positivity. TN and H2E tumors are 




Since the practical predictive factors are not 
sufficiently categorized in breast cancer, further 
information is required for determining the prognosis 
and more specific treatments. The stroma surrounding 
cancer cells affects the tumor progression, tumor 
grade, and the tumor behavior in various organs. 
Various studies described the role of tumor stroma 
components in invasive breast cancer and the presence 
of tumor-derived atrophic stromal cells, fibroblasts, 
especially in fibrotic areas, is associated with 
metastatic tumor recurrence and death due to tumor. 
For this reason, this study attempted to examine the 
relationship between stroma components with tumor 
grade and tumor types. All of the above-mentioned 
factors are related to tumor prognosis in invasive 
breast cancers and new prognostic factors were 
proposed. Such factors are not only effective in the 
overall prognosis of the patient but also in the 
diagnostic and background criteria for new therapies. 
Based on the previous studies, stromal reactions 
including lymphocytic infiltrating, desmoplasic 
reaction, its type, as well as the presence and absence 
of necrosis. In another study by Gujam et al. (2014) on 
361 patients with ductal carcinoma of the breast, it was 
found that high rates of tumor stroma were associated 
with a higher incidence and lower survival rate in 
tumor-suppressed tumors
16
. In addition, Matsumoto 
(2015) on 27 cases found that the level of Tumor 
Infiltrating Lymphocytes (TIL) in basal-like and her 2 
patients is clearly higher than that of the luminal group 
resulting in better response to neoadjuvant therapy and 
an increase in pathological complete response (PCR)
17
 
.Despite extensive research on the molecular markers 
of breast cancer, the observed differences in the results 
and the effects of demographic factors on the status of 
these biomarkers highlighted the importance of further 
studies in different areas
13
. In recent years, few studies 
have been reported regarding the status of biomarkers 
in breast cancer and their relationship with PR, ER, 
p53, HER2/neu and other prognostic factors in breast 
cancer, most of which were limited to the relationship 
between prognostic biomarkers and clinical and 
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pathological characteristics of breast cancer
18
. The 
present study was conducted on the patients with 
breast cancer to determine the relationship between 
stromal factors and tumor biomarker classification in 
breast cancer and recognize the biomarkers as 
prognostic factors in breast cancer. 
Methods 
This study is a cross-sectional type in which 108 
breast cancer pathology slides were studied for 
diagnosing breast cancer with grading pathology, 
stromal components, and immunophenotype 
components, during 2011-2017 from the department 
of pathology in Imam Hossein Hospital (Tehran 
Iran). The research findings were analyzed in terms 
of the relationship between stromal components and 
stromal component reactions including the presence 
of lymphocytic infiltrating, the presence or absence 
of a fibrous region in the tumor and its type, and the 
presence of necrosis and its rate. The other histologic 
findings such as tumor necrosis grafts, histological 
grade, tumor type, and invasive tumors were 
evaluated for histochemical markers such as ER, PR, 
HER2 and Ki67.  
Tumor infiltrating lymphocytes in breast cancer: 
Specific genes in triple tumors control a kind of host 
immune response to tumor tissue and its increase is 
unexpectedly associated with a worse prognosis in 
breast tumors. In this reaction, the lymphocyte 
population is heterogeneous. Heterogeneous means 
the mixture of lymphocytes with CD3 or CD4 
markers. Several lymphocyte models can be 
infiltrated in the tumor tissue: Intra tumor infiltrating 
lymphocyte (TIL): It is observed inside the tumor 
nests and tumor cells and is not significant in terms 
of response to treatment and prognosis; Stromal TIL: 
It is observed around the tumor cell nests, which is 
important in determining the prognosis of response to 
treatment; The presence of lymphocytic follicles is 
usually found around the tumor tissue. Although it 
reflects the host's immune response, it is not valuable 
in determining the prognosis. 
Significant criteria for TIL evaluation including: TIL 
is expressed as a percentage; TIL evaluation is 
important on the margins of the invasive tumor and 
within the stroma surrounding the tumor; 
Lymphocytes outside the margin of the tumor are not 
measured around the DCIS and the normal lobules; 
Lymphocytes in areas of artifact, necrosis, 
healenization, and position of previous biopsy are not 
included in the evaluation; All single-cell 
inflammatory cells (lymphocytes and plasma cells) are 
evaluated and neutrophils are excluded from this 
category; Examination of complete samples is 
preferable to needle samples. In addition, evaluating 
the samples is not conducted after the Neoadjuvant 
therapy; Average lymphocytes are reported by the 
pathologist; The percentages are reported as complete 
numbers, e.g. 15% instead of 13.5%. 
In this study, the evaluation of TIL was expressed as a 
semi-quantitative parameter. For example, when TIL 
is 80%, it means that 80% of stromal regions indicate 
strong infiltrating of mononuclear cells
19-21
.  
The evaluation criteria of stromal fibrosis around 
the tumor: The desmoplacial or fibrotic reaction 
around the tumor is divided into three groups of 
mature, immature, and intermediate. 
Mature: It happens when collagen fibers around the 
tumor are long and thin in several layers. 
Intermediate: Thick fibers of collagen with bright 
Eosinophilic hyalinization similar to a colloid tissue 
are around the tumor. 
Immature: Collagen fibers similar to Colloidal are 
randomly surrounded by a loose stroma
22
.  
In addition, Tumor necrosis was investigated in the 
presence or absence of necrosis and its rate was 
extensive (over 50% of tissue) and non-extensive (less 
than 50% of tissue). During this study, the 
experimental results of the ER, PR, HER-2/neu and 
Ki67 markers in the patient’s file were used. The 
variables were analyzed by SPSS software version 22, 
T-Test, and Chi-square (Determining the exact method 
of data analysis is possible after obtaining data and 
data features). Preserving the personal secrets and 
patient characteristics were considered during the 
study. 
Based on a study the minimum required sample size 
was calculated to be 110 by using a sample size 
formula for comparative studies and considering 80% 




In this study, there were 108 patients with a mean and 
standard deviation of 50.84 ± 13.55 years (range of 
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25-89 years). Luminal B group with 36 subjects 
(33.3%) had the maximum frequency followed by the 
basal like group with 35 subjects (32.4%), HER-
2/neu with 22  subjects (22.4%) and luminal A group 
with 15 subjects (15.9%). In the present study, there 
was no significant relationship between age and type 
of groups (p>0.05). In terms of pathological grade 
among the three grades of disease, the majority of 
patients (60%) were in grade 2. Thereafter, there were 
grade 1 (23%), grade 3 (17.6%) and only a significant 
difference was observed between the three groups of 
luminal B, HER2/neu, Basal like and grade 2 (p<0.05). 



























































 Basal 25 4 6 3 19 13 10 21 4 35 
HER2 13 1 8 3 17 2 5 14 3 22 
LuminalA 5 0 10 6 8 1 6 5 4 15 
LuminalB 16 1 19 13 20 3 7 24 5 36 
Total 59 6 43 25 64 19 28 10 21 4 
 
Table 3: Relationship between biological type of tumor and stromal factors. 
 Basal HER2 LuminalB LuminalA 
Pathological grade 0.004 <0.001 0.002 0.074 
Desmoplasia 0.002 0.009 <0.001 0.819 
Lymphocytes rate 0.078 0.886 0.003 0.692 
Tumor necrosis <0.001 0.007 <0.001 0.197 
 
Table 1: Frequency of the studied lams based on necrosis, pathological grade, and desmoplasia. 
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The relationship between age and disease grade was 
not significant (p>0.05). In terms of desmoplasia, 
most patients in all four pathological groups had 
intermediate desmoplasia which was significant only 
between the three groups of luminal B, HER2/neu, 
Basal-like and intermediate desmoplasia (p<0.05). In 
terms of tumor necrosis rate, the majority of patients 
in the HER2/neu and Basal-like groups indicated 
non-extensive necrosis, which was significant 
(p>0.05). In both groups of luminal, A and luminal 
B, most patients did not have necrosis while the 
association between necrosis and pathological type of 
tumor was significant only in the luminal B group 
(p>0.05). In terms of the number of lymphocytes, the 
HER2/neu group with a mean of 35% lymphocyte in 
the tumor was ranked first followed by the luminal A 
group with a mean of 30% lymphocyte, the luminal 
B group with 28% and the basal like group with 
24.9% lymphocyte. No significant relationship was 
obtained between the number of lymphocytes and the 
type of tumor. In this study, the patients were studied 
in terms of pathological grade that highest 
pathological grade among these patients was grade 2 
and 59.3% (64 patients).  
In this study, the lymphocyte rate of patients was 
quantitatively analyzed while 29.29±25.18 mean and 
standard deviation of lymphocyte rate among the 
subjects. The highest and lowest lymphocyte rates 
were 90 and 2, respectively. Based on the findings, 
the relationship between tumors was evaluated in this 
study in terms of tumor necrosis rate. In this study, 
Chi-square test was used to analyze the research data 
and the relationship between each variable and the 
type of tumors was investigated. In Table 3, the type 
of tumor represents p-value for each variable 
showed. 
Based on the findings of this study, the relationship 
between age and pathological grade was evaluated 
and the difference in mean was reported between 
each group. In addition, no significant was reported 
the relationship between the within-groups and 
between-groups. 
Discussion 
The present study aimed at classifying the breast 
tumors in terms of ER, PR, KI67 and HER2/neu 
markers expression (molecular and biological 
classification) and studying its relationship with 
stromal reactions as prognostic factors in invasive 
breast carcinoma.  
In this study, the related data for 110 patients were 
extracted and two patients were excluded due to 
incomplete information. In the present study, the 
majority of patients (33%) were in the luminal B 
group and then in the basal group. Furthermore, the 
luminal A group had the lowest prevalence (13.8%) 
among the four groups. 
In addition, regarding age and disease grade, no 
significant relationship was observed between age and 
three grades of disease and the patients with a higher 
or lower age indicated no higher grade (p>0.05). In 
terms of pathological grade among the three grades of 
disease, the majority of patients (60%) had grade 2. 
Finally, 23% and 17.6% had grade 1 and 3. A 
significant relationship was observed between the 
three groups of luminal B, HER2/neu, basal-like and 
grade 2 (p<0.05). In other words, most patients with 
these biomarkers who were in these three groups 
indicated grade 2 while this relationship was 
insignificant in the luminal A group (p>0.05).  
In terms of desmoplasia in all four pathological 
groups, most patients had intermediate desmoplasia. A 
significant relationship was found between the three 
groups of luminal B, HER2/neu, basal-like and 
intermediate desmoplasia (p<0.05). The patients 
having these biomarkers in these three groups 
indicated intermediate desmoplasia. In the luminal A 
group, unlike most other groups, most patients 
indicated immature desmoplasia while this 
relationship was insignificant in the luminal A group 
(p>0.05).  
In terms of tumor necrosis rate, the HER2/neu and 
basal-like groups mostly indicated the non-extensive 
necrosis patients, which was significant. In other 
words, the patients indicated non-extensive necrosis in 
the HER2/neu and basal-like groups (p>0.05). 
In both groups of luminal A and B, most patients had 
no necrosis. However, the relationship between 
necrosis and pathological type of tumor was 
significant in the luminal B group (p>0.05) while this 
relationship was not significant in the luminal A 
group. In the present study, the HER2/neu group was 
in the first place with an average of 35% lymphocyte 
in the tumor. 
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 Luminal A group with 30% lymphocyte, luminal B 
group with 28%, and basal-like group with 24.9% 
lymphocytes were in the next ranks. However, no 
significant relationship was reported between the 
number of lymphocytes and the type of tumor 
(p>0.05).  
In another study by Kadivar et al. in Rasoul Akram 
and Atiyeh Hospitals in Tehran, 60 patients with 
breast tumors under 40 years of age and 57 patients 
with breast tumors over 60 years of age were 
included in the study. No significant difference was 
found between the size of the tumor, lymphatic 
involvement, histological grade, tumor stage, PR, 
ER, and HER2/neu in the group under 40 years of 




In another study by Keyhanian et al. 220 women with 
breast cancer were studied. Research findings 
indicated that 77.3% of patients were 55 years of age 
and 35% of patients were postmenopausal. Excessive 
expression of HER2/neu was found in 38.2% and 
P53 gene mutation was observed in 52.3% of 
patients. ER in 69.1% and PR in 63.6% of cases were 
positive. In the recent study, there was a significant 
relationship between HER2/neu biomarker with 
tumor size, between P53 biomarker status with tumor 
pathology, ER biomarker with stage of disease and 
tumor pathological grade, and PR biomarker with 
stage of disease and tumor pathological grade. In 
addition, no significant relationship was reported 
between the status of biomarkers and prognostic 
factors in this study (p>0.05)
24
. Since two biomarkers 
PR and ER are common in both groups of luminal A 
and B, other biomarkers including Ki67 were used in 
this study for differentiation of these two biomarkers. 
Results of pathological grade were different from the 
above-mentioned study, due to use of other 
biomarkers in the present study and group 
classification.  
In addition, Behrouz Najafi et al. (2006) considered 
the relationship between HER-2 and other clinical 
diagnostic criteria in breast cancer patients and the 
relationship between HER2 membrane protein and 
other clinicopathological parameters such as tumor 
grade, presence of absence of lympho-vascular 
invasion and its association with the status of steroid 
receptors and P53 in patients with breast cancer. This 
descriptive-analytical study was performed on 465 
patients with breast cancer referring to two cancer 
centers of Guilan province (North of Iran) during 
2000-2005. An immunohistochemical semi-
quantitative method was used for HER2 receptor P53 
receptor protein and steroid receptors. As a result, 32% 
of patients had HER2-positive protein. The presence of 
HER2 protein was significantly associated with P53 
(p=0.000). In addition, the presence of HER2 protein 
was related to the lack of steroid receptors with high 
grade pathological tumors (grade 3). Further, the 
absence of HER2 protein was associated with the 
presence of steroidal receptors with a lower grade of 
tumor grade (grade 1). Furthermore, no significant 
relationship was observed between HER2, Lympho-
vascular invasion, tumor size, and recurrence. 
Therefore, the presence of HER2 protein in patients 
with breast cancer was significantly associated with 
tumor differentiation grade and the presence of HER2 
protein was related to other prognostic factors such as 
the lack of steroid receptor or presence of P53
25
. In 
another study by Matsumoto, studied on 27 cases, it 
was found that the level of tumor infiltrating 
lymphocytes (TIL) in basal-like and HER2 patients 
was clearly higher than luminal group resulting in 
better response to neoadjuvant therapy and an increase 
in pathological complete response (PCR). The present 
study indicated a higher rate of TIL in HER2 group
17
.  
Histopathological studies on 114 breast cancer patients 
indicated a strong correlation between immature 
desmoplastic reaction and axillary lymph node 
involvement. This study emphasized the role of 
desmoplastic reaction
23
. A comprehensive study in 
2017 on 3771 patients with breast cancer indicated that 
the higher levels of TIL in the inner tissue of tumor in 
the basal-like and HER2 patients were associated with 
better response to neoadjuvant therapy and 
immunotherapy. The effect of this stromal reaction on 





Based on the research findings indicating the 
relationship between pathological types of breast 
tumors based on pathologic grade biomarkers, necrosis 
rate, tumor desmoplacial rate, TIL and determining the 
pathological type of tumor based on the status of 
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biological markers (HER2/neu PR, ER, Ki67) is 
recommended to decide on the treatment plan on 
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